


**Supplementary Figure 1.** Time-dependent receiver-operator-characteristic curves of symptom duration with DMARD-free sustained remission during 5-year follow-up as outcome for methotrexate users (A,C) and patients using other conventional DMARDs (B,D) in the EAC (A,B) and ESPOIR (C,D); the symptom duration with the best discriminative ability was determined using Youden's index.



**Supplementary Figure 2.** Time-dependent receiver-operator-characteristic curves of symptom duration with DMARD-free sustained remission during 5-year follow-up as outcome for ACPA-positive (A) and ACPA-negative (B) RA-patients in the EAC.

